This study is a randomized, double-blind, placebo controlled, multicenter study with two parallel groups of patients.
The study will be conducted in 5 Italian clinical sites and will involve 250 patients receiving at least 2 cycles of highly emetogenic treatments.
Patients will be randomly assigned